著者
Toshiyuki Noda Kazuhiko Nishigaki Shinya Minatoguchi
出版者
The Japanese Circulation Society
雑誌
Circulation Journal (ISSN:13469843)
巻号頁・発行日
pp.CJ-20-0307, (Released:2020-06-11)
参考文献数
14

Background:Because ST-elevation myocardial infarction (STEMI) extensively damages the heart, regenerative therapy with pluripotent stem cells such as multilineage-differentiating stress enduring (Muse) cells is required.Methods and Results:In a first-in-human study, 3 STEMI patients with a left ventricular ejection fraction (LVEF) ≤45% after successful percutaneous coronary intervention received intravenously 1.5×107cells of a human Muse cell-based product, CL2020. The safety and efficacy on LVEF and wall motion score index (WMSI) were evaluated for 12 weeks. No adverse drug reaction was noted. LVEF and WMSI were markedly improved.Conclusions:The first-in-human intravenous administration of CL2020 was safe and markedly improved LV function in STEMI patients.

言及状況

外部データベース (DOI)

Twitter (15 users, 15 posts, 71 favorites)

生命科学インスティテュート:急性心筋梗塞を対象としたMuse細胞(CL2020)の探索的臨床試験の結果論文。 有効性は声高に主張していないにせよ、3人に投与しただけで安全性を示したと言えるのだろうか? 天下の三菱ケミカル系でもこの状況、、
#読んだ これはどうなんだろう / Safety and Efficacy of Human Muse Cell-Based Product for Acute Myocardial Infarction in a First-in-Human Trial https://t.co/c8C706OIen

収集済み URL リスト